In8Bio (INAB) Accumulated Depreciation (2020 - 2026)
In8Bio (INAB) posted Accumulated Depreciation of $3.4 million for Q1 2026, up 7.66% sequentially from $3.2 million in Q4 2025, and up 36.72% YoY from $2.5 million in Q1 2025.
In8Bio (INAB) Accumulated Depreciation (2020 - 2026) Analysis & Trends
In8Bio has reported Accumulated Depreciation for 7 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Accumulated Depreciation rose 36.72% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 36.72% YoY) and the FY2025 annual result came in at $3.2 million, up 41.36% from the prior year.
- Accumulated Depreciation grew to $3.4 million in Q1 2026 per INAB's latest filing, from $3.2 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $3.4 million in Q1 2026 and troughed at $321000.0 in Q4 2022.
- A 5-year average of $1.5 million and a median of $1.3 million in 2023 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation fell 7.23% in 2022, then jumped 299.69% in 2023.
- Over 5 years, Accumulated Depreciation stood at $321000.0 in 2022, then surged by 299.69% to $1.3 million in 2023, then soared by 76.38% to $2.3 million in 2024, then soared by 41.36% to $3.2 million in 2025, then rose by 7.66% to $3.4 million in 2026.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $3.4 million, $3.2 million, and $2.5 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.44 Mn |
| Dec 31, 2025 | 3.20 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.52 Mn |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 807,000.00 |
| Mar 31, 2023 | 564,000.00 |
| Dec 31, 2022 | 321,000.00 |
| Sep 30, 2022 | 417,000.00 |
| Jun 30, 2022 | 384,000.00 |
| Mar 31, 2022 | 362,000.00 |
| Dec 31, 2021 | 346,000.00 |
| Sep 30, 2021 | 324,000.00 |
| Jun 30, 2021 | 301,000.00 |
| Dec 31, 2020 | 257,000.00 |